Published :
Tables : 47
Figures : 39
Category : Healthcare
No. of Pages : 211
Report Code : HC-U2930
Opioids Drugs Market is forecasted to value over USD 31 billion by 2027 end and register a CAGR of 2.5% from the forecast period 2020-2027. FutureWise Market Research has instantiated a report that provides an intricate analysis of Opioids Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market. According to the research study conducted by FutureWise research analysts, the Opioids Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Opioids Drugs Market are: PURDUE PHARMA TEVA MYLAN J&J DEPOMED INSYS Acura Pharmaceuticals Inc Allergan Plc Biodelivery Sciences International Inc Cipher Pharmaceuticals Inc Collegium Pharmaceutical Inc Daiichi Sankyo Inc Egalet Corp Hikma Pharmaceuticals Plc Indivior Inc Janssen Pharmaceuticals Inc Lannett Co. Inc Lupin Ltd Mylan Nv Pfizer Inc Sanofi-aventis S.A Sun Pharmaceutical Industries Limited (Sun Pharma) (Note: The list of the major players will be updated with the latest market scenario and trends) Opioids Drugs Market Segmentation: By Type • Buprenorphine • Fentanyl • Hydrocodone • Morphine • Oxycodone • Tramadol • Others By Application • Pain Relief o Cancer Pain o Postoperative Pain Management o Low Back Pain o Orthopedic o Fibromyalgia o Neuropathic • Anesthesia • Cough Suppression • Diarrhea Suppression • Deaddiction By Region • North America • Europe • Asia-Pacific • Rest of the world Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Opioids Drugs Market by type, by application and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Opioids Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market. According to the research study conducted by FutureWise research analysts, the Opioids Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Opioids Drugs Market are:
Opioids Drugs Market Segmentation:
By Type • Buprenorphine • Fentanyl • Hydrocodone • Morphine • Oxycodone • Tramadol • Others
By Application • Pain Relief o Cancer Pain o Postoperative Pain Management o Low Back Pain o Orthopedic o Fibromyalgia o Neuropathic • Anesthesia • Cough Suppression • Diarrhea Suppression • Deaddiction
By Region • North America • Europe • Asia-Pacific • Rest of the world
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Opioids Drugs Market by type, by application and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Opioids Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Opioids Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Opioids Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Buprenorphine 7.2.Fentanyl 7.3.Hydrocodone 7.4.Morphine 7.5.Oxycodone 7.6.Tramadol 7.7.Others 8. Global Opioids Drugs Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1.Pain Relief 8.1.1. Cancer Pain 8.1.2. Postoperative Pain Management 8.1.3. Low Back Pain 8.1.4. Orthopedic 8.1.5. Fibromyalgia 8.1.6. Neuropathic 8.2.Anesthesia 8.3.Cough Suppression 8.4.Diarrhea Suppression 8.5.Deaddiction 9. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2020-2027 10. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. Germany 10.2.2. U.K 10.2.3. France 10.2.4. Italy 10.2.5. Spain 10.2.6. Russia 10.2.7. Poland 10.2.8. Switzerland 10.2.9. Rest of Western Europe 11. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. Japan 11.2.2. China 11.2.3. Singapore 11.2.4. India 11.2.5. Australia and New Zealand 11.2.6. ASEAN 11.2.7. South Korea 11.2.8. Rest of Asia Pacific 11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 12. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Saudi Arabia 12.2.2. UAE 12.2.3. South Africa 12.2.4. Egypt 12.3. Market Size (USD Million) Forecast for MEA 2020-2027 13. Rest of the World Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2020-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 14.1. PURDUE PHARMA 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. TEVA 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. MYLAN 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. J&J 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. DEPOMED 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. INSYS 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Acura Pharmaceuticals Inc 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Allergan Plc 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Biodelivery Sciences International Inc 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Cipher Pharmaceuticals Inc 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 14.11. Collegium Pharmaceutical Inc 14.11.1. Company Overview 14.11.2. Product Portfolio 14.11.3. SWOT Analysis 14.11.4. Financial Overview 14.11.5. Strategic Overview 14.12. Daiichi Sankyo Inc 14.12.1. Company Overview 14.12.2. Product Portfolio 14.12.3. SWOT Analysis 14.12.4. Financial Overview 14.12.5. Strategic Overview 14.14. Egalet Corp 14.13.1. Company Overview 14.13.2. Product Portfolio 14.13.3. SWOT Analysis 14.13.4. Financial Overview 14.13.5. Strategic Overview 14.14. Hikma Pharmaceuticals Plc 14.14.1. Company Overview 14.14.2. Product Portfolio 14.14.3. SWOT Analysis 14.14.4. Financial Overview 14.14.5. Strategic Overview 14.15. Indivior Inc 14.15.1. Company Overview 14.15.2. Product Portfolio 14.15.3. SWOT Analysis 14.15.4. Financial Overview 14.15.5. Strategic Overview 14.16.Janssen Pharmaceuticals Inc 14.16.1. Company Overview 14.16.2. Product Portfolio 14.16.3. SWOT Analysis 14.16.4. Financial Overview 14.16.5. Strategic Overview 14.17. Lannett Co. Inc 14.17.1. Company Overview 14.17.2. Product Portfolio 14.17.3. SWOT Analysis 14.17.4. Financial Overview 14.17.5. Strategic Overview 14.18. Lupin Ltd 14.18.1. Company Overview 14.18.2. Product Portfolio 14.18.3. SWOT Analysis 14.18.4. Financial Overview 14.18.5. Strategic Overview 14.19. Mylan Nv 14.19.1. Company Overview 14.19.2. Product Portfolio 14.19.3. SWOT Analysis 14.19.4. Financial Overview 14.19.5. Strategic Overview 14.20. Pfizer Inc 14.20.1. Company Overview 14.20.2. Product Portfolio 14.20.3. SWOT Analysis 14.20.4. Financial Overview 14.20.5. Strategic Overview 14.21. Sanofi-aventis S.A 14.21.1. Company Overview 14.21.2. Product Portfolio 14.21.3. SWOT Analysis 14.21.4. Financial Overview 14.21.5. Strategic Overview 14.22. Sun Pharmaceutical Industries Limited (Sun Pharma) 14.22.1. Company Overview 14.22.2. Product Portfolio 14.22.3. SWOT Analysis 14.22.4. Financial Overview 14.22.5. Strategic Overview 15. FutureWise SME key takeaway points for Client
1. Market Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.3.2 Market Covered
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2. Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3. Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.3 Competitive Insights
4. Global Opioids Drugs Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework
4.6.1. Reimbursement Framework
4.6.2. Standards And Compliances
5. Market Overview
5.1. Market Dynamics
5.1.1. Market Driver Analysis
5.1.1.1. Increasing focus on Brand Protection
5.1.1.2. Untapped Opportunities in Emerging Regions
5.1.2. Market Restraint Analysis
5.1.3. Industry Challenges
5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Opioids Drugs Market Analysis Tools
6.1. Industry Analysis - Porter’s
6.1.1. Supplier Power
6.1.2. Buyer Power
6.1.3. Substitution Threat
6.1.4. Threat from New Entrants
6.1.5. Competitive Rivalry
6.2. Pestel Analysis
6.2.1. Political Landscape
6.2.2. Environmental Landscape
6.2.3. Social Landscape
6.2.4. Technology Landscape
6.2.5. Legal Landscape
6.3. Major Deals And Strategic Alliances Analysis
6.3.1. Joint Ventures
6.3.2. Mergers and Acquisitions
6.3.3. Licensing and Partnership
6.3.4. Technology Collaborations
6.3.5. Strategic Divestments
6.4. Market Entry Strategies
6.5. Case Studies
7. Global Opioids Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
7.1. Buprenorphine
7.2.Fentanyl
7.3.Hydrocodone
7.4.Morphine
7.5.Oxycodone
7.6.Tramadol
7.7.Others
8. Global Opioids Drugs Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
8.1.Pain Relief
8.1.1. Cancer Pain
8.1.2. Postoperative Pain Management
8.1.3. Low Back Pain
8.1.4. Orthopedic
8.1.5. Fibromyalgia
8.1.6. Neuropathic
8.2.Anesthesia
8.3.Cough Suppression
8.4.Diarrhea Suppression
8.5.Deaddiction
9. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
9.1. Introduction
9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
9.2.1. U.S.A
9.2.2. Canada
9.2.3. Mexico
9.3. Market Size (USD Million) Forecast for North America 2020-2027
10. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
10.1. Introduction
10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
10.2.1. Germany
10.2.2. U.K
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Russia
10.2.7. Poland
10.2.8. Switzerland
10.2.9. Rest of Western Europe
11. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs
11.1. Introduction
11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
11.2.1. Japan
11.2.2. China
11.2.3. Singapore
11.2.4. India
11.2.5. Australia and New Zealand
11.2.6. ASEAN
11.2.7. South Korea
11.2.8. Rest of Asia Pacific
11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
12. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
12.2.1. Saudi Arabia
12.2.2. UAE
12.2.3. South Africa
12.2.4. Egypt
12.3. Market Size (USD Million) Forecast for MEA 2020-2027
13. Rest of the World Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
13.1. Introduction
13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
13.2.1. Saudi Arabia
13.2.2. UAE
13.2.3. South Africa
13.2.4. Egypt
13.3. Market Size (USD Million) Forecast for MEA 2020-2027
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
14.1. PURDUE PHARMA
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.3. SWOT Analysis
14.1.4. Financial Overview
14.1.5. Strategic Overview
14.2. TEVA
14.2.1. Company Overview
14.2.2. Product Portfolio
14.2.3. SWOT Analysis
14.2.4. Financial Overview
14.2.5. Strategic Overview
14.3. MYLAN
14.3.1. Company Overview
14.3.2. Product Portfolio
14.3.3. SWOT Analysis
14.3.4. Financial Overview
14.3.5. Strategic Overview
14.4. J&J
14.4.1. Company Overview
14.4.2. Product Portfolio
14.4.3. SWOT Analysis
14.4.4. Financial Overview
14.4.5. Strategic Overview
14.5. DEPOMED
14.5.1. Company Overview
14.5.2. Product Portfolio
14.5.3. SWOT Analysis
14.5.4. Financial Overview
14.5.5. Strategic Overview
14.6. INSYS
14.6.1. Company Overview
14.6.2. Product Portfolio
14.6.3. SWOT Analysis
14.6.4. Financial Overview
14.6.5. Strategic Overview
14.7. Acura Pharmaceuticals Inc
14.7.1. Company Overview
14.7.2. Product Portfolio
14.7.3. SWOT Analysis
14.7.4. Financial Overview
14.7.5. Strategic Overview
14.8. Allergan Plc
14.8.1. Company Overview
14.8.2. Product Portfolio
14.8.3. SWOT Analysis
14.8.4. Financial Overview
14.8.5. Strategic Overview
14.9. Biodelivery Sciences International Inc
14.9.1. Company Overview
14.9.2. Product Portfolio
14.9.3. SWOT Analysis
14.9.4. Financial Overview
14.9.5. Strategic Overview
14.10. Cipher Pharmaceuticals Inc
14.10.1. Company Overview
14.10.2. Product Portfolio
14.10.3. SWOT Analysis
14.10.4. Financial Overview
14.10.5. Strategic Overview
14.11. Collegium Pharmaceutical Inc
14.11.1. Company Overview
14.11.2. Product Portfolio
14.11.3. SWOT Analysis
14.11.4. Financial Overview
14.11.5. Strategic Overview
14.12. Daiichi Sankyo Inc
14.12.1. Company Overview
14.12.2. Product Portfolio
14.12.3. SWOT Analysis
14.12.4. Financial Overview
14.12.5. Strategic Overview
14.14. Egalet Corp
14.13.1. Company Overview
14.13.2. Product Portfolio
14.13.3. SWOT Analysis
14.13.4. Financial Overview
14.13.5. Strategic Overview
14.14. Hikma Pharmaceuticals Plc
14.14.1. Company Overview
14.14.2. Product Portfolio
14.14.3. SWOT Analysis
14.14.4. Financial Overview
14.14.5. Strategic Overview
14.15. Indivior Inc
14.15.1. Company Overview
14.15.2. Product Portfolio
14.15.3. SWOT Analysis
14.15.4. Financial Overview
14.15.5. Strategic Overview
14.16.Janssen Pharmaceuticals Inc
14.16.1. Company Overview
14.16.2. Product Portfolio
14.16.3. SWOT Analysis
14.16.4. Financial Overview
14.16.5. Strategic Overview
14.17. Lannett Co. Inc
14.17.1. Company Overview
14.17.2. Product Portfolio
14.17.3. SWOT Analysis
14.17.4. Financial Overview
14.17.5. Strategic Overview
14.18. Lupin Ltd
14.18.1. Company Overview
14.18.2. Product Portfolio
14.18.3. SWOT Analysis
14.18.4. Financial Overview
14.18.5. Strategic Overview
14.19. Mylan Nv
14.19.1. Company Overview
14.19.2. Product Portfolio
14.19.3. SWOT Analysis
14.19.4. Financial Overview
14.19.5. Strategic Overview
14.20. Pfizer Inc
14.20.1. Company Overview
14.20.2. Product Portfolio
14.20.3. SWOT Analysis
14.20.4. Financial Overview
14.20.5. Strategic Overview
14.21. Sanofi-aventis S.A
14.21.1. Company Overview
14.21.2. Product Portfolio
14.21.3. SWOT Analysis
14.21.4. Financial Overview
14.21.5. Strategic Overview
14.22. Sun Pharmaceutical Industries Limited (Sun Pharma)
14.22.1. Company Overview
14.22.2. Product Portfolio
14.22.3. SWOT Analysis
14.22.4. Financial Overview
14.22.5. Strategic Overview
15. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics